Literature DB >> 1399950

Comparative in-vitro activity of RP 59500 against clinical bacterial isolates.

M Inoue1, R Okamoto, T Okubo, K Inoue, S Mitsuhashi.   

Abstract

The activity of RP 59500 against Gram-positive cocci was determined by an agar dilution method and compared with that of erythromycin, cefotaxime and ampicillin. Of the 344 clinical isolates tested, none was resistant to RP 59500; this compound was active both against methicillin-resistant Staphylococcus aureus and against macrolide-resistant Gram-positive cocci. The bactericidal activity of RP 59500 was confirmed by killing curve determinations.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1399950     DOI： 10.1093/jac/30.suppl_a.45

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


  10 in total

1.  Plasmid-encoded metallo-beta-lactamase (IMP-6) conferring resistance to carbapenems, especially meropenem.

Authors:  H Yano; A Kuga; R Okamoto; H Kitasato; T Kobayashi; M Inoue
Journal:  Antimicrob Agents Chemother       Date:  2001-05       Impact factor: 5.191

Review 2.  Quinupristin/dalfopristin: a review of its use in the management of serious gram-positive infections.

Authors:  H M Lamb; D P Figgitt; D Faulds
Journal:  Drugs       Date:  1999-12       Impact factor: 9.546

3.  Pulsed-field gel electrophoresis analysis of nasopharyngeal flora in children attending a day care center.

Authors:  H Yano; M Suetake; A Kuga; K Irinoda; R Okamoto; T Kobayashi; M Inoue
Journal:  J Clin Microbiol       Date:  2000-02       Impact factor: 5.948

4.  In vitro activity of quinupristin/dalfopristin and newer quinolones combined with gentamicin against resistant isolates of Enterococcus faecalis and Enterococcus faecium.

Authors:  E J Giamarellos-Bourboulis; H Sambatakou; P Grecka; H Giamarellou
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-09       Impact factor: 3.267

Review 5.  Streptogramins. A unique class of antibiotics.

Authors:  J C Pechère
Journal:  Drugs       Date:  1996       Impact factor: 9.546

6.  In vitro activity of LY333328, an investigational glycopeptide antibiotic, against enterococci and staphylococci.

Authors:  R S Schwalbe; A C McIntosh; S Qaiyumi; J A Johnson; R J Johnson; K M Furness; W J Holloway; L Steele-Moore
Journal:  Antimicrob Agents Chemother       Date:  1996-10       Impact factor: 5.191

Review 7.  Quinupristin-dalfopristin.

Authors:  H M Bryson; C M Spencer
Journal:  Drugs       Date:  1996-09       Impact factor: 9.546

Review 8.  Antibacterial activity of quinupristin/dalfopristin. Rationale for clinical use.

Authors:  R G Finch
Journal:  Drugs       Date:  1996       Impact factor: 9.546

9.  Treatment of experimental endocarditis due to erythromycin-susceptible or -resistant methicillin-resistant Staphylococcus aureus with RP 59500.

Authors:  J M Entenza; H Drugeon; M P Glauser; P Moreillon
Journal:  Antimicrob Agents Chemother       Date:  1995-07       Impact factor: 5.191

Review 10.  Role of macrolide therapy in chronic obstructive pulmonary disease.

Authors:  Fernando J Martinez; Jeffrey L Curtis; Richard Albert
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2008
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.